

1 **FGF21 defines a potential cardio-hepatic signaling circuit in human heart**  
2 **failure.**

3 Salah Sommakia<sup>1</sup>, Naredos H. Almaw<sup>1</sup>, Sandra H. Lee<sup>1</sup>, Dinesh K. A. Ramadurai<sup>1</sup>, Iosef  
4 Taleb<sup>1</sup>, Christos P. Kyriakopoulos<sup>1</sup>, Chris J. Stubben<sup>2</sup>, Jing Ling<sup>1</sup>, Robert A. Campbell<sup>3</sup>,  
5 Rami A. Alharethi<sup>4</sup>, William T. Caine<sup>4</sup>, Sutip Navankasattusas<sup>1</sup>, Guillaume L. Hoareau<sup>1</sup>,  
6 <sup>5</sup>, Anu E. Abraham<sup>6</sup>, James C. Fang<sup>6</sup>, Craig H. Selzman<sup>4</sup>, Stavros G. Drakos<sup>1, 6</sup>, Dipayan  
7 Chaudhuri<sup>1, 6</sup>

8 Nora Eccles Harrison Cardiovascular Research and Training Institute, University of  
9 Utah, Salt Lake City, UT, USA

10 Bioinformatics Shared Resource, Huntsman Cancer Institute, University of Utah, Salt  
11 Lake City, UT 84112

12 Department of Internal Medicine, Division of General Medicine, Program in Molecular  
13 Medicine, University of Utah, Salt Lake City, UT, USA

14 U.T.A.H. (Utah Transplant Affiliated Hospitals) Cardiac Transplant Program: University  
15 of Utah Healthcare and School of Medicine, Intermountain Medical Center, Salt Lake  
16 Veterans Affairs Health Care System, Salt Lake City, UT.

17 Emergency Medicine Division, Department of Surgery, University of Utah, Salt Lake  
18 City, UT, USA.

19 Department of Internal Medicine, Division of Cardiovascular Medicine, University of  
20 Utah, Salt Lake City, UT

21 Correspondence:

22 Dipayan Chaudhuri  
23 95 South 2000 East  
24 CVRTI (Building 500)  
25 Salt Lake City, UT 84112  
26 [dipayan.chaudhuri@hsc.utah.edu](mailto:dipayan.chaudhuri@hsc.utah.edu)  
27 801-585-3682

28

29 **ABSTRACT**

30 Background: Extrinsic control of cardiac contractility and ultrastructure via  
31 neurohormonal signaling is well established, but how other organs regulate  
32 cardiomyocyte metabolism is less well understood. Fibroblast growth factor-21 (FGF21)  
33 a hormonal regulator of metabolism mainly produced in the liver and adipose tissue, is a  
34 prime candidate for such signaling.

35 Methods: To investigate this further, we examined blood and tissue obtained from  
36 human subjects with heart failure with reduced ejection fraction (HFrEF) at the time of  
37 left ventricular assist device (LVAD) implantation, and correlated serum FGF21 levels  
38 with cardiac gene expression, immunohistochemistry, and clinical parameters.

39 Results: Circulating FGF21 levels were substantially elevated in HFrEF, compared to  
40 healthy subjects (HFrEF:  $834.4 \pm 101.8$  pg/mL,  $n = 40$ ; controls:  $145.9 \pm 28.6$  pg/mL,  $n$   
41  $= 20$ ,  $p = 5.5 \times 10^{-8}$ ). There was clear FGF21 staining in diseased cardiomyocytes, and  
42 circulating FGF21 levels negatively correlated with the expression of cardiac genes  
43 involved in ketone metabolism, consistent with cardiac FGF21 signaling. FGF21 gene  
44 expression was low in failing and non-failing hearts, suggesting at least partial  
45 extracardiac production of the circulating hormone. Circulating FGF21 levels were  
46 correlated with BNP and total bilirubin, markers of chronic cardiac and hepatic  
47 congestion.

48 Conclusions: Circulating FGF21 levels are elevated in HFrEF. The liver is likely the main  
49 extracardiac source, and congestive hepatopathy, common in HFrEF, was likely the  
50 proximate signal leading to FGF21 elevations. This supports a model of venous

51 congestion from cardiomyopathy driving hepatic FGF21 communication to diseased  
52 cardiomyocytes, defining a potential cardio-hepatic signaling circuit in human heart  
53 failure.

## 54 **INTRODUCTION**

55 A central feature of heart failure across different etiologies is a profound alteration in  
56 cardiomyocyte metabolism<sup>1</sup>. In heart failure with reduced ejection fraction (HFrEF),  
57 notable changes include increased reliance on glucose, ketones, and short-chain fatty  
58 acids, reduced pyruvate uptake by mitochondria and a consequent shunting of glycolysis  
59 towards the pentose-phosphate pathway<sup>2-5</sup>. Such adaptations are associated with altered  
60 expression of cardiomyocyte genes involved in the transport and metabolism of these  
61 different substrates. Some of these changes are dependent on cardiomyocyte-intrinsic  
62 signaling pathways triggered by cardiac dysfunction, but extrinsic control of  
63 cardiomyocyte metabolism is not well understood. Since extrinsic control via  $\beta$ -  
64 adrenergic and renin-angiotensin neurohormonal regulation is well established for  
65 cardiomyocyte contractility and ultrastructure, it seems likely such mechanisms exist to  
66 alter cardiomyocyte metabolism as well.

67 To explore extrinsic cardiometabolic signaling, we focused on fibroblast growth factor-  
68 21 (FGF21). This cytokine of the FGF19/21/23 family is produced primarily in the liver  
69 and adipose tissue, and is a potent regulator of fuel utilization and metabolism. Due to  
70 the absence of heparin-binding domains, secreted FGF21 can travel into the  
71 bloodstream and act as a hormone, binding to a receptor complex composed of a  
72 tyrosine kinase FGF receptor isoform and the  $\beta$ -Klotho (KLB) co-receptor. FGF21

73 regulates fatty acid oxidation in the liver, insulin sensitivity, glucose metabolism in  
74 adipose cells, and ketone usage<sup>6</sup>. In humans, FGF21 has been explored as a metabolic  
75 biomarker. In healthy subjects, it is induced late during the adaptive response to  
76 starvation<sup>7</sup>, but also during short-term carbohydrate overfeeding<sup>8</sup>, alcohol  
77 consumption<sup>9</sup>, and cold-induced thermogenesis<sup>8</sup>. Increased hepatic and adipose  
78 secretion is widely noted in diabetes and obesity, and skeletal muscle expression is  
79 noted after exercise or in hyperinsulemic states<sup>10-14</sup>.

80 Cardiomyocyte FGF21 signaling appears to be protective in several animal models of  
81 heart disease. In mouse models of hypertensive heart disease, deletion of FGF21 led to  
82 faster adverse cardiac remodeling, whereas application of exogenous FGF21 prevented  
83 cardiomyocyte hypertrophy<sup>15, 16</sup>. The effect seemed partly mediated by the reduction of  
84 fibrotic and inflammatory markers, but also by preventing a maladaptive decrease in  
85 PGC1 $\alpha$ , the transcriptional co-factor regulating cardiac energy metabolism. In mouse  
86 models of myocardial ischemia-reperfusion injury, FGF21 deletion was associated with a  
87 greater reduction in cardiac function, which could be rescued by administering FGF21<sup>17</sup>.  
88 In this setting, improved cardiac function was associated with reduced markers of  
89 cardiomyocyte apoptosis. However, in studies of high-fat diets, mice were either  
90 protected or impaired after FGF21 deletion<sup>18-20</sup>. Nevertheless, data from these several  
91 disease studies seem to converge on a model revealing direct FGF21 action on the heart.  
92 However, FGF21 signaling in heart disease remains unresolved in humans. In  
93 particular, whereas FGF21 appears protective in most animal models of heart disease,  
94 elevated levels are poor prognostic indicators in humans. In two studies of diabetic  
95 patients with coronary disease, higher levels of FGF21 were predictive of poorer

96 outcomes<sup>21, 22</sup>. In cardiomyopathies, FGF21 elevations predicted adverse events in both  
97 heart failure with reduced or preserved ejection fraction, though >40% of patients in  
98 both these studies had diabetes<sup>23, 24</sup>. Additionally, whether the elevated blood FGF21 is  
99 synthesized in the heart itself or is produced in other organs remains unresolved. In  
100 mouse studies, FGF21 appears to be synthesized in diseased or metabolically-altered  
101 hearts, but not healthy cardiomyocytes, though cardiac expression was not seen in other  
102 studies<sup>15, 16, 18, 25, 26</sup>. Human data is scant, with one study showing an increase in FGF21  
103 transcripts and two showing FGF21 staining in cardiomyocytes in alcoholic  
104 cardiomyopathy or hypertensive heart disease, all from a single group<sup>26-28</sup>. Thus, the  
105 extent of FGF21 elevation during HFrEF, what signals trigger this elevation, and  
106 whether it is active in the heart, remain unresolved questions.

107 Here, to investigate cardiac FGF21 biology independent of its well-established elevation  
108 during diabetes, we took advantage of cardiac tissue collection during the implantation  
109 of left ventricular assist devices (LVAD) in non-diabetic patients with end-stage HFrEF.  
110 First, we find that circulating FGF21 levels are elevated in HFrEF, and appear to act  
111 specifically upon failing cardiac tissue. Second, the concentration of circulating FGF21  
112 correlates with markers of congestive hepatopathy, suggesting that the liver injury is a  
113 major trigger for its extracardiac secretion. Thus, FGF21 appears to be a novel hormone  
114 affecting cardiac function during periods of venous hepatic congestion.

## 115 **RESULTS**

116 We retrospectively analyzed serum samples, obtained at the time of left ventricular  
117 assist device (LVAD) implantation, in 40 patients with ischemic and nonischemic  
118 HFrEF. Because we specifically wanted to determine the effect of heart failure on FGF21

119 levels, none of these patients had diabetes, end-stage renal failure, viral hepatitis, or  
120 non-alcoholic fatty liver disease (NAFLD), conditions known to alter FGF21 levels<sup>11, 29-31</sup>.  
121 A description of patient characteristics is included in Table 1.

122 We measured blood FGF21 levels using an enzyme-linked immunosorbent assay. For  
123 controls, we utilized plasma from 20 age- and gender-matched healthy controls.  
124 Circulating FGF21 levels were more than fivefold higher in HFREF patients compared to  
125 controls ( $834.4 \pm 101.8$  pg/mL vs.  $145.9 \pm 28.6$  pg/mL, mean  $\pm$  SEM, Figure 1A). In  
126 prior studies of FGF21 in human cardiomyopathies, a substantial fraction of patients  
127 had diabetes, a comorbidity expected to raise FGF21. Our results here show the increase  
128 in FGF21 during HFREF is not due only to concurrent diabetes or NAFLD. Within the  
129 HFREF group, no difference was observed in serum FGF21 between females and males  
130 ( $822.7 \pm 156.5$  pg/mL vs.  $841.4 \pm 135.5$  pg/mL, Figure 1B), or between ischemic and  
131 non-ischemic etiologies ( $691.1 \pm 133.9$  pg/mL vs.  $895.8 \pm 133.4$  pg/mL, Figure 1C).  
132 There was no correlation with the age of the subject (Figure 1D). In a subset of patients  
133 with mechanically-unloaded failing hearts, cardiac structure and function improves to  
134 the point that some of these patients can be weaned from mechanical support, and we  
135 assessed whether FGF21 level might predict such myocardial function improvement. In  
136 our cohort, recovery was defined as an improvement in left ventricular ejection fraction  
137 to  $>40\%$  and reduction in left ventricular end-diastolic diameter to  $\leq 59$  mm. However,  
138 there was no significant difference in serum FGF21 between patients who recovered left  
139 ventricular function during mechanical unloading (responder,  $774.2 \pm 171.9$  pg/mL,  
140 Figure 1E) and those that did not (non-responder,  $860.2 \pm 127.1$  pg/mL).

141 In mouse studies of cardiac injury due to pathological hypertrophy, inflammation, and

142 ischemia, FGF21 signaling has been seen within the heart<sup>15, 26</sup>, but whether such heart-  
143 specific expression occurs in humans remains unresolved, with a single study showing  
144 upregulation in cardiac tissue in people with end-stage heart failure<sup>26</sup>. We addressed  
145 two specific questions. First, whether FGF21 is found within heart tissue in HFrEF,  
146 which would define the human heart as a locus for FGF21 signaling. Second, whether  
147 the elevated serum levels are due to cardiac FGF21 synthesis.

148 To address the first question, whether FGF21 signals to the heart during HFrEF, we  
149 stained cardiac sections with anti-FGF21 antibodies in a subset of the HFrEF patients.  
150 As control, we examined cardiac sections in structurally intact hearts obtained from  
151 non-failing donors, but unused for human heart transplantation due to non-cardiac  
152 reasons. Although hearts in these donors were structurally and functionally normal, the  
153 donors themselves were deceased due to traumatic or anoxic brain injury, critical  
154 illnesses in which circulating FGF21 levels have been found to be elevated<sup>32-35</sup>. Our  
155 results replicated these findings, with donor serum FGF21 levels elevated ( $810 \pm 225$   
156 pg/mL,  $n = 5$ ) as in HFrEF serum. This set of conditions allows us to clearly identify if  
157 cardiac dysfunction leads to FGF21 signaling. In fact, whereas sections from donors  
158 showed essentially no cardiac FGF21 staining, sections obtained from HFrEF patients  
159 showed robust labeling throughout cardiomyocytes (Figure 2). This difference in  
160 cardiomyocyte staining is not due to altered levels of circulating FGF21, as serum levels  
161 were similarly elevated in both donor and HFrEF subjects. Rather, this result  
162 establishes that the failing heart is preferentially primed for FGF21-mediated metabolic  
163 signals.

164 Next, we addressed whether the FGF21 staining seen in heart sections represented a

165 fraction bound from the elevated circulating levels or protein synthesized within  
166 cardiomyocytes. To address this issue, we assessed the expression of cardiac genes  
167 related to FGF21 signaling (Figure 3). Because the limited amounts of tissue obtained  
168 per patient are used in various assays across multiple studies, precluding Western blot  
169 analyses of protein levels, we restricted our analysis to measuring transcript levels via  
170 quantitative reverse-transcriptase polymerase chain reaction (qPCR). When we  
171 examined *FGF21* transcripts with qPCR, we found expression was near the limits of  
172 detection. Moreover, there was no clear change in expression between donor and HFrEF  
173 patients, nor any correlation with serum FGF21 levels (Figure 3), suggesting the *FGF21*  
174 gene may have low cardiac expression. To further assess cardiac *FGF21* transcription,  
175 we examined 7 published RNA-seq datasets obtained from cardiac tissue in human  
176 patients with ischemic, non-ischemic, restrictive, and hypertrophic cardiomyopathies  
177 (Table 2). *FGF21* transcripts were detectable in only 14 out of 167 samples, primarily in  
178 cardiomyopathy samples, and in most of these cases corresponded to 1-2 reads. Given  
179 limited cardiac FGF21 synthesis, it appears elevated circulating FGF21 during HFrEF  
180 may have a primarily extracardiac source. However, though FGF21 is synthesized  
181 elsewhere, it clearly signals to the heart, given the robust FGF21 staining we found in  
182 cardiac tissue in HFrEF, but not donors. Taken together, these results reveal an  
183 unexpected metabolic signaling axis to the heart from organs synthesizing FGF21.

184 As a first step towards examining cardiac FGF21 signaling in humans, we also assayed  
185 genes involved in the FGF response and fuel metabolism via qPCR (Figure 3). FGF21  
186 exerts its effects primarily by binding to a receptor complex composed of one of four  
187 tyrosine kinase FGF receptor isoforms, typically FGFR1, and the  $\beta$ -Klotho (KLB) co-



188 receptor<sup>36</sup>. In our hands, there was no evidence for a net increase in gene expression of  
189 FGF receptors nor the co-receptor  $\beta$ -Klotho between HFrEF versus donor samples.  
190 Intriguingly, however, there was a strong positive correlation between serum FGF21 and  
191 cardiac *FGFR3* expression. In contrast, most samples had suppressed *FGFR4*  
192 expression. We then turned to genes involved in the metabolism of glucose, fatty acids,  
193 and ketones. Compared to donor heart tissue, HFrEF cardiac samples had increased  
194 levels of *pyruvate dehydrogenase kinase 4 (PDK4)*, which inhibits the conversion of  
195 pyruvate into acetyl-CoA, as well as several genes involved in the transport and  
196 metabolism of ketones, including *solute carrier family 16 member 7 (SLC16A7* or  
197 *MCT2)*, a monocarboxylate transporter responsible for ketone uptake, *3-*  
198 *hydroxybutyrate dehydrogenase (BDH1)*, which catalyzes the interconversion between  
199 the ketones  $\beta$ -hydroxybutyrate and acetoacetate, and *3-oxoacid-CoA transferase*  
200 (*OXCT1* or *SCOT*), which transfers the CoA group to the ketone acetoacetate.  
201 Unexpectedly, we found a negative correlation between serum FGF21 levels and *BDH1*  
202 transcripts, and similar but much weaker trends with the *SLC16A1* and *SLC16A7*  
203 transporters. This result was intriguing, as prior mouse studies revealed that inhibition  
204 of FGF21 reduced *Bdh1* transcripts, opposite to the correlation found here<sup>37</sup>. Although  
205 these analyses of correlations do not establish a particular mechanism for cardiac FGF21  
206 activity, they do lend support to the hypothesis that FGF21 may act as a hormonal  
207 regulator of cardiac metabolism.

208 Our results established that serum FGF21 in HFrEF is elevated in the absence of overt  
209 metabolic diseases such as diabetes or NAFLD. To investigate the source of FGF21  
210 production, we correlated serum FGF21 levels with the available clinical data on

211 adiposity and cardiac, hepatic, and renal function (Figure 4). Notably, advanced HFrEF  
212 is associated with a cachectic phenotype, and elevated FGF21 levels have been attributed  
213 to muscle wasting during cardiac cachexia or prolonged fasting<sup>7, 38</sup>. In our cohort,  
214 however, we found no correlation with body-mass index (BMI) or aspartate  
215 aminotransferase (AST), a liver marker also released during muscle breakdown in  
216 cachectic states. Intriguingly, we observed the most significant correlation with B-type  
217 natriuretic peptide (BNP), followed by total bilirubin. Increased BNP is a sensitive  
218 marker for chronic pathological cardiomyocyte stretch, a condition associated with  
219 vascular congestion. Similarly, elevated total bilirubin in the absence of elevated liver  
220 function enzymes (AST) is the pattern encountered most frequently in congestive  
221 hepatopathy, which also occurs due to chronic vascular (venous) congestion. This  
222 suggests that chronic venous congestion may be a proximal signal for hepatic FGF21  
223 secretion. Moreover, we observed a weak negative correlation with albumin, a marker of  
224 hepatic synthetic function, and stronger negative correlations with triglycerides and  
225 total cholesterol, which also partly reflect hepatic synthesis. We did not pursue  
226 correlations with invasive hemodynamic data, as these acute measures were optimized  
227 in the immediate preoperative period prior to LVAD implantation. Taken together, our  
228 data here supports the hypothesis that one main source of elevated circulating FGF21  
229 observed in HFrEF is due to hepatic release.

## 230 **DISCUSSION**

231 This study describes three major findings defining human cardiac FGF21 biology. First,  
232 serum levels of FGF21 are elevated in the setting of HFrEF independent of other  
233 comorbidities, such as diabetes, that can raise hormone concentration. Second, FGF21 is

234 present in cardiomyocytes from failing but not donor hearts, suggesting that it may  
235 activate downstream cardiac signals. Third, the origin of the elevated FGF21 appears to  
236 be partly extracardiac, with the liver as the most likely extracardiac source.

237 Elevated serum FGF21 levels have been seen in prior studies of heart failure with either  
238 reduced or preserved ejection fraction<sup>23, 24, 38</sup>. The aim of all three studies was to  
239 evaluate FGF21 as a biomarker for cardiac disease, rather than to elucidate human  
240 cardiac FGF21 biology. In two studies, diabetes was a significant comorbidity in >40% of  
241 subjects, confounding the ability to interpret the basis for elevated FGF21<sup>23, 24</sup>. In the  
242 third study, diabetic patients were excluded. In that study, serum FGF21 levels were  
243 elevated in 19 HFrEF patients and increased further in 19 subjects with HFrEF and  
244 cachexia, defined as a 5% non-edematous weight loss over 6 months. Notably, the  
245 HFrEF study by Shen *et. al.* was powered to detect cardiovascular outcomes, and  
246 elevated FGF21 levels predicted cardiac death independently of N-terminal pro-BNP  
247 levels<sup>24</sup>. More broadly, elevated FGF21 levels have been associated with adverse cardiac  
248 events in individuals with coronary disease and/or diabetes, though in subclinical  
249 disease such elevations are no longer predictive after adjustment for traditional risk  
250 factors<sup>21, 22, 39, 40</sup>. Thus, elevated FGF21 is a potential biomarker for severity in cardiac  
251 disease, raising the question of what derangements are causing this elevation, and  
252 whether the elevated FGF21 is an intrinsic or hormonal signal for the diseased heart.

253 The source of FGF21 signaling to the heart has been difficult to resolve. Initial studies  
254 suggested minimal expression in the mouse heart, whereas subsequent studies showed  
255 upregulation at both transcript and protein levels during cardiac hypertrophy<sup>15, 41</sup>.

256 Conversely, in another study of FGF21 protection in a mouse model of hypertensive

257 heart disease, circulating FGF21 was thought to arise from brown adipose tissue during  
258 adenosine receptor agonism<sup>16</sup>. In the only study of human cardiac gene expression,  
259 transcriptomic analysis revealed somewhat increased FGF21 expression during end-  
260 stage HFrEF<sup>26</sup>. In our qPCR data, whereas elevated transcription was seen in particular  
261 HFrEF samples, a uniform increase was not detected, corroborated by analysis of  
262 previously published transcriptomic datasets. Taken together, this suggests that cardiac  
263 FGF21 gene expression is low at baseline, with perhaps a slight, heterogeneous increase  
264 in cardiomyopathies.

265 Nevertheless, our data here is consistent with mouse and human data showing direct  
266 activity of circulating FGF21 on the heart<sup>15, 18, 27, 28</sup>. Robust cardiac FGF21 staining was  
267 seen in all the HFrEF samples but none of the non-failing donors, suggesting that  
268 elevated circulating FGF21 binds to the failing heart. In terms of cardiac regulation, in  
269 hypertrophy and ischemic models, exogenous FGF21 reduced fibrosis, inflammation,  
270 apoptosis, and maladaptive changes in cardiac energy metabolism<sup>15-17, 19</sup>. In this report,  
271 we queried a range of genes involved in cardiac metabolism. Surprisingly, we found an  
272 overall negative correlation between FGF21 and genes involved in the synthesis and  
273 transport of ketones. Whereas some prior data has suggested a direct relationship  
274 between FGF21 and fasting-induced ketogenesis, in humans the ketogenic response  
275 seems to precede the release of FGF21, suggesting a more circuitous relationship<sup>7, 37</sup>.  
276 Since our data is entirely correlational, we can only speculate that FGF21 acting on the  
277 heart may be a compensatory signal to preserve energetic homeostasis during  
278 progressive contractile failure. Intriguingly, there must definitely be changes in the  
279 response or susceptibility to circulating FGF21 during cardiomyopathies, as we saw no

280 significant FGF21 staining in functionally normal hearts collected from donors, despite  
281 these individuals having similarly elevated serum FGF21 levels. In examining the FGF  
282 receptor family, we saw no obvious transcriptional upregulation that would indicate how  
283 FGF21 binds cardiomyocytes during HFrEF, though there was a strong positive  
284 correlation with *FGFR3*, and possibly transcriptional suppression of *FGFR4*.

285 Finally, we investigated the pathology responsible for elevating blood FGF21. The liver is  
286 the primary source of FGF21, though adipose tissue also produces it. It is likely the  
287 elevated FGF21 in HFrEF derives from the liver rather than adipose tissue, as we saw no  
288 relationship with BMI, and, when increased FGF21 levels are due to adipose release, it  
289 shows a positive correlation with lipid profile<sup>11, 42</sup>. Instead, here we find higher FGF21  
290 associated with a lower lipid levels, which may reflect the triglyceride-lowering effect of  
291 exogenous FGF21<sup>43, 44</sup>. In regards to the mechanism activating hepatic FGF21 secretion,  
292 our data revealed a strong correlation between FGF21 and BNP levels, a marker of  
293 chronic myocardial stretch and vascular congestion. We also showed a correlation with  
294 elevated bilirubin but not AST, a pattern most consistent with congestive hepatopathy,  
295 which is also due to chronic vascular congestion. In summary, pathological hepatic  
296 venous congestion in HFrEF may be the proximate signal causing FGF21 release, with  
297 elevated FGF21 feeding back on the heart to regulate its metabolism. Thus, FGF21  
298 defines a potential cardio-hepatic metabolic signaling loop in HFrEF.

## 299 **LIMITATIONS**

300 First, although we assay a variety of clinical indexes, cardiac gene expression, and  
301 cardiac FGF21 protein, our analysis is based on correlations between these parameters,  
302 and a causal pathway has not been established. Without corresponding liver samples

303 from these patients, we cannot confirm the serum FGF21 source is hepatic. Second, we  
304 did not study clinical outcomes. Our study was not powered or designed for clinical  
305 outcomes, as HFREF patients went on to LVAD implantation and, for a substantial  
306 number of individuals, cardiac transplants. Finally, we studied a subset of patients with  
307 advanced HFREF without diabetes, end-stage renal failure, or several other forms of  
308 liver disease. The biological activity of FGF21 may be more complex when these  
309 comorbidities are present, or when the early stages of heart failure are investigated.

## 310 **METHODS**

### 311 **Study Population**

312 The HFREF cohort was taken from a larger sample of patients enrolled at the time of  
313 LVAD implantation. Patients who required LVAD support due to acute heart failure  
314 (acute myocardial infarction, acute myocarditis, and others) were prospectively  
315 excluded. Patients (age  $\geq$  18-years) were consecutively enrolled in institutions  
316 comprising the Utah Transplantation Affiliated Hospitals (U.T.A.H.) Cardiac Transplant  
317 Program (University of Utah Health Science Center, Intermountain Medical Center, and  
318 the Veterans Administration Salt Lake City Health Care System) with clinical  
319 characteristics consistent with dilated cardiomyopathy and chronic advanced heart  
320 failure who required circulatory support with continuous-flow LVAD. Non-failing donor  
321 hearts, not allocated for heart transplantation due to non-cardiac reasons (size,  
322 infection, and others) were used as controls. The study was approved by the institutional  
323 review board of the participating institutions, and informed consent was provided by all  
324 patients.

325 In the current study, we selected patients from the overall study who had blood samples  
326 available and who did not have diabetes (clinical diagnosis or hemoglobin A1c < 6.5%),  
327 overt renal failure (creatinine < 1.2 mg/dL), a clinical diagnosis of non-alcoholic fatty  
328 liver disease or viral hepatitis.

329 Blood samples used as the control reference were from healthy subjects recruited from  
330 the University of Utah and the surrounding Mountain West states. All subjects provided  
331 written, informed consent and all study protocols were IRB approved. Age- and gender-  
332 matched healthy donors were medication free and without acute or chronic illnesses.

### 333 **Blood and Myocardial Tissue Acquisition**

334 Myocardial tissue was prospectively collected from the LV apical core at the time of  
335 LVAD implantation and was frozen before storage at -80 °C. Control samples were  
336 acquired from hearts that were not transplanted due to non-cardiac reasons. Donor LV  
337 apical tissue was harvested and processed the same way as the failing hearts. For HFrEF  
338 and donor samples, blood was collected immediately prior to the beginning of the  
339 operation. For healthy control samples, blood was collected by venipuncture. Samples  
340 were centrifuged and serum or plasma collected and stored for later analysis.

### 341 **Clinical Data Collection**

342 Donor information like age, sex, and cause of death were collected with the help of  
343 DonorConnect. For HFrEF patients, clinical data including demographics,  
344 comorbidities, echocardiographic parameters, laboratory results, and other clinical data  
345 were collected within one week before LVAD implantation using our institutional  
346 research electronic data capture system (REDCap). We followed the echocardiographic

347 data of each participant after surgery for up to 12 months. Based on left ventricular  
348 functional and structural changes following at least 3 months on LVAD support, patients  
349 were categorized as either responder or non-responder (see definitions in Results).

### 350 **Blood FGF21 measurements**

351 Serum or plasma FGF21 levels were measured using the Quantikine ELISA Human  
352 FGF21 kit (R&D Systems, Minneapolis, coefficient of variation: Intra-Assay, 3.4%, Inter-  
353 assay 7.5%) according to the manufacturer's instructions. Our control values were  
354 similar to prior studies conducted in either serum or plasma with this kit, and its  
355 accuracy has been validated in both<sup>45-50</sup>. Samples were run in duplicate. For each well,  
356 50  $\mu$ L standard or undiluted plasma or serum was added to 100  $\mu$ L assay diluent,  
357 incubated for 2h at room temperature, washed 4X, then 200  $\mu$ L conjugate was added to  
358 each well and incubated for 2h at room temperature. Wells were washed 4X, then 200  
359  $\mu$ L substrate solution was added and incubated for 30 min at room temperature,  
360 protected from light, then 50  $\mu$ L stop solution was added to each well. Absorbance  
361 readings at 450 nm were recorded immediately following the addition of the stop  
362 solution, with a wavelength correction reading at 540 nm.

### 363 **Immunohistochemistry**

364 The anti-FGF21 antibody (Abcam, ab171941) was used. Tissue pieces were fixed in 10%  
365 buffered formalin and embedded in paraffin. Sections 6  $\mu$ m thick were made using a  
366 vibratome and mounted on coverglass. Sections were deparaffinized using Histosol  
367 (Fisher Scientific) then rehydrated by successively submerging in 100%, 95%, 70%  
368 ethanol followed by distilled H<sub>2</sub>O. Antigen retrieval was performed by submerging



369 slides in antigen retrieval buffer (containing 60 mM sodium citrate and 40 mM citric  
370 acid, pH = 6.0) and heating in a microwave at a gentle boil for 10 minutes. Each section  
371 was then washed in wash buffer (containing 150mM NaCl, 50mM Tris pH=7.8, and  
372 0.025% v/v Tween-20), permeabilized by incubation in permeabilization buffer  
373 (containing 150mM NaCl, 50mM Tris pH=7.8, 0.2% v/v Tween-20, and 1% w/v bovine  
374 serum albumin (BSA) for 15 minutes at room temperature, then washed 3X in wash  
375 buffer. Sections were then incubated in blocking buffer (containing 150 mMNaCl, 50  
376 mM Tris pH=7.8, 0.025% v/v Tween-20, 10% v/v goat serum, and 1% w/v BSA) for 1  
377 hour at room temperature, then in primary antibody buffer (containing 150 mMNaCl,  
378 50 mM Tris pH=7.8, 0.025% v/v Tween-20, 1% w/v BSA, and 1:200 primary antibody)  
379 overnight at 4C. The following day, sections were washed 3X 5 minutes in wash buffer  
380 then incubated in oxidation buffer (containing 150 mMNaCl, 50 mM Tris pH=7.8,  
381 0.025% v/v Tween-20, and 0.3%v/v H<sub>2</sub>O<sub>2</sub>) for 15 minutes at room temperature,  
382 followed by one wash in wash buffer. Sections were then incubated in secondary  
383 antibody buffer (containing 150 mMNaCl, 50 mM Tris pH=7.8, 0.025% v/v Tween-20,  
384 1% w/v BSA, and 1:500 secondary antibody) for 1 hour at room temperature. Sections  
385 were then washed 3X with wash buffer and developed with DAB solution according to  
386 manufacturer's instructions, washed 3X with wash buffer, then washed 3x with MilliQ  
387 H<sub>2</sub>O. Sections were counterstained with Mayer's hematoxylin for 1 minute at room  
388 temperature, washed 3X with 10mM NaOH, then 3X with MilliQ H<sub>2</sub>O. Sections were  
389 then coverslipped using IHC mounting medium. Images were taken using an Olympus  
390 DSP camera mounted on an optical microscope.

### 391 **Cardiac FGF21 gene expression measurement**

392 RNA was isolated from the LV tissue samples using the miRNeasy Mini Kit (Qiagen) or  
393 Purelink RNA Mini Kit (Thermo). Single strand complementary DNA (cDNA) was  
394 generated using Superscript Vilo IV master mix (Thermo) according to the  
395 manufacturer's instructions using 1 µg RNA. cDNA was diluted 1:10 with Ultrapure  
396 distilled water (Thermo Fisher). Reactions were performed with 300 nM primers, using  
397 Power SYBR Green PCR Master Mix (Thermo) per the manufacturer's  
398 recommendations. Quantification of gene expression was performed on a 96-well CFX  
399 Real-Time PCR System (BioRad). Analysis was performed by using the 2- $\Delta\Delta$ Ct method,  
400 using the housekeeping gene *RPLP0*. Primers were based on prior publications,  
401 designed on NCBI Primer -BLAST, or obtained from Primerbank. A list of primers is  
402 below.

<u>Gene</u>	<u>Primer</u>
<i>ACACB</i>	CAAGCCGATCACCAAGAGTAAA CCCTGAGTTATCAGAGGCTGG
<i>BDH1</i>	GTGTAGAAGCGTCCGGGTG GCAACGGGTGTTAGAATGGC
<i>CPT1B</i>	GAGCAGCACCCCAATCAC AACTCCATAGCCATCATCTGCT
<i>FGF21</i>	CAGCGGTACCTCTACACAGATG GCTTTCAGCTGCAGGAGACT
<i>FGFR1</i>	GTCTGCTGACTCCAGTGCAT ACGGTTGGGTTTGTCTTGT
<i>FGFR2</i>	ACAGTTTCGGCTGAGTCCAG GGTGTCTGCCGTTGAAGAGA
<i>FGFR3</i>	CCCTACGTTACCGTGCTCAA CAATAGAATTGCCCGCCAGG
<i>FGFR4</i>	GTGGGCAGCATCCGCTATAA CCATGTGGGGTCTCCTCTG
<i>KLB</i>	AGATGTGCAGGGCCAGTTT GCCACAGACTCGGGCTTA
<i>OXCT1</i>	TGAGGCGCTGAGAGGAACTT GAGAGGAGTTTGAGAGCCGC
<i>PDK1</i>	CTGTGATACGGATCAGAAACCG

*PDK4* TCCACCAAACAATAAAGAGTGCT  
GGAGCATTTCTCGCGCTACA  
ACAGGCAATTCTTGTGCGCAA  
*RPLP0* TGGTCATCCAGCAGGTGTTTGA  
ACAGACACTGGCAACATTGCGG  
*SLC2A1* ATGGCCGGGGTCCTATAAAC  
TGTAGCCAAACTGCAGGGAG  
*SLC16A1* AGGTCCAGTTGGATACACCCC  
GCATAAGAGAAGCCGATGGAAAT  
*SLC16A7* GGGTTGGATTGTGGTTGGAG  
TCCTGCGTACATAACAGCCAG

### 403 **Analysis of RNA-Seq Datasets**

404 The NCBI Gene Expression Omnibus was searched for datasets obtained from human  
405 cardiac tissue, restricted to published studies on ischemic, nonischemic, hypertrophic,  
406 and restrictive cardiomyopathies using bulk RNA-Seq technology. We did not use  
407 single-cell RNA-Seq studies, because few were currently available and there is ongoing  
408 uncertainty about the interpretation of few or no reads per cell. We extracted metadata  
409 regarding samples, gene counting methods, and read format from the series matrix file,  
410 and raw or normalized count data for *FGF21* expression (searching for FGF21,  
411 ENSG00000105550, or ENST00000222157) from the supplementary data files. One  
412 dataset (GSE55296) was excluded as sample information was unavailable, one dataset  
413 (GSE65446) was excluded as the original study had been retracted. In these excluded  
414 studies FGF21 was either filtered out due to low expression or present in only the  
415 minority of individuals at low levels, similar to the presented data. The presented  
416 analysis includes seven datasets collected between 2014 and 2021.

### 417 **Statistics**

418 Student's *t*-test assuming unpaired, unequal variance samples were used for two-sample

419 comparisons, assuming significance for  $p < 0.05$ . Correlations were performed using  
420 linear regression, with p-values for the coefficient of determination ( $r^2$ ) calculated from  
421 an analysis of variance using the *F*-statistic. For multiple hypothesis testing, a  
422 Benjamini-Hochberg procedure was used to derive corrected p-values (q-values) using a  
423 false discovery rate of 0.05. Analyses were performed in Excel and OriginPro 2020.

## 424 **FIGURE LEGENDS**

425 **Figure 1. Circulating FGF21 levels are elevated in HFrEF. A.** FGF21 levels in  
426 healthy controls (n=20) versus patients with HFrEF (n=40). **B.** No difference in FGF21  
427 levels across gender in HFrEF patients (female = 15, male = 25). **C.** No difference in  
428 FGF21 levels between ischemic (n=12) and non-ischemic (n=28) HFrEF. **D.** No  
429 correlation with age of patient. Red line represents linear regression fit to the data, with  
430 pink shaded area representing 95% confidence bands. **E.** No difference in FGF21  
431 between responders (n=18) and non-responders (n=22). Bars represent mean  $\pm$  SEM.  
432 Each dot represents the level for an individual subject here and throughout.

## 433 **Figure 2. FGF21 is present in cardiomyocytes from HFrEF patients.**

434 Immunostaining for FGF21 in human heart slices reveals little FGF21 present in donor  
435 hearts but robust staining in HFrEF hearts. Nuclei are labelled in blue and FGF21  
436 immunostaining is brown. Each panel is from a different patient.

## 437 **Figure 3. Correlations between serum FGF21 and cardiac gene expression.**

438 For each gene listed above, the left panel is the relative gene expression between normal  
439 donor (DON, n=4-6) and HFrEF hearts (HF, n=9-17). The right panel for each gene  
440 shows the linear regression for the HFrEF hearts against serum FGF21 (sFGF21) levels.

441 The red line is the linear regression, with shaded area corresponding to 95% confidence  
 442 bands. Coefficient of determination ( $r^2$ ) and corresponding Benjamini-Hochberg  
 443 corrected p value (q) for a false discovery rate of 0.05 are shown.

444 **Figure 4. Correlations between serum FGF21 and clinical parameters.**

445 Correlation of serum FGF21 values with clinical index via linear regression (n=34-40).  
 446 The red line is the linear regression, with shaded area corresponding to 95% confidence  
 447 bands. Coefficient of determination ( $r^2$ ) and corresponding Benjamini-Hochberg  
 448 corrected p value (q) for a false discovery rate of 0.05 are shown.

449  
 450 **Table 1. Characteristics of study population**

	Heart Failure	Controls	Donors
N	40	20	9
Age (years)	48.1±18.3	48.1±19.6	44.0±7.4
Women	15 (37.5%)	11 (55%)	5 (55.6%)
Hispanic/Black/White/Other	3/2/33/2	NA	0/0/8/1
Smoker	17 (42.5%)	NA	NA
Body Mass Index			
LVEF (%)	19 ± 6	NA	60 ± 7
LVEDD (cm)	6.5 ± 0.7	NA	4.1 ± 0.4
Ischemic HFrEF	12 (30%)	0	0
Non-ischemic HFrEF:	28 (70%)		
Idiopathic	19 (48%)		
Peripartum	3 (8%)	0	0
Drug-induced	2 (5%)		
Valvular	2 (5%)		
Other	2 (5%)		
B-type natriuretic peptide (pg/mL)	1440 ± 1290	NA	NA
Hemoglobin A1C	5.7 ± 0.4	NA	5.4 ± 0.4
Serum creatinine (mg/dL)	0.9 ± 0.2	NA	0.9 ± 0.4
Blood urea nitrogen (mg/dL)	17.9 ± 6.8	NA	16.3 ± 9.8
Aspartate aminotransferase (Units/L)	45.6 ± 35.9	NA	100 ± 81.5

Albumin (g/dL)	3.7 ± 0.6	NA	2.7 ± 0.5
Total bilirubin (mg/dL)	1.2 ± 0.7	NA	1.0 ± 0.4
Triglycerides (mg/dL)	107.1 ± 45.3	NA	NA
Total Cholesterol (mg/dL)	139.7 ± 46.4	NA	NA
Beta-blocker	22 (55%)	NA	NA
ACE-I	20 (50%)	NA	NA
ARB	4 (10%)	NA	NA
Aldosterone Blocker	19 (47.5%)	NA	NA
Diuretics	37 (92.5%)	NA	NA
Aspirin	17 (42.5%)	NA	NA
Clopidogrel	3 (7.5%)	NA	NA
Anti-arrhythmics	14 (35%)	NA	NA


Values are counts or mean ± standard deviation. NA: not available; ACE-I: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter

451  
452  
453

**Table 2. Human cardiomyopathy RNA-Seq datasets**


Dataset (Ref.)	Cardiomyopathy Type	Total Samples	Detectable FGF21 transcripts – Non-failing (positive/total)	Detectable FGF21 transcripts – Cardiomyopathy (positive/total)
GSE135055 <sup>51</sup>	HFrEF	30	0/7	0/23
GSE71613 <sup>52</sup>	HFrEF, Restrictive	8	0/4	2/4
GSE57344 <sup>53</sup>	HFrEF	6	1/3	1/3
GSE46224 <sup>54</sup>	HFrEF	40	0/8	1/32
GSE160997 <sup>55</sup>	Hypertrophic	23	0/5	2/18
GSE133054 <sup>56</sup>	HFrEF, Hypertrophic	23	0/8	5/15
GSE130036 <sup>57</sup>	Hypertrophic	37	0/9	2/28
		167	1/44	13/123

454  
455



456

457 **FIGURE 1**




458


459 **FIGURE 2**

460





461  
 462 **FIGURE 3**  
 463  
 464



465  
466 **FIGURE 4**  
467  
468

469 **REFERENCES**

- 470 1. Lopaschuk GD, Karwi QG, Tian R, Wende AR and Abel ED. Cardiac Energy Metabolism  
471 in Heart Failure. *Circ Res*. 2021;128:1487-1513.
- 472 2. Carley AN, Maurya SK, Fasano M, Wang Y, Selzman CH, Drakos SG and Lewandowski  
473 ED. Short-Chain Fatty Acids Outpace Ketone Oxidation in the Failing Heart. *Circulation*.  
474 2021;143:1797-1808.
- 475 3. Cluntun AA, Badolia R, Lettlova S, Parnell KM, Shankar TS, Diakos NA, Olson KA, Taleb  
476 I, Tatum SM, Berg JA, Cunningham CN, Van Ry T, Bott AJ, Krokidi AT, Fogarty S, Skedros S,  
477 Swiatek WI, Yu X, Luo B, Merx S, Navankasattusas S, Cox JE, Ducker GS, Holland WL,  
478 McKellar SH, Rutter J and Drakos SG. The pyruvate-lactate axis modulates cardiac hypertrophy  
479 and heart failure. *Cell Metab*. 2021;33:629-648.e10.
- 480 4. Badolia R, Ramadurai DKA, Abel ED, Ferrin P, Taleb I, Shankar TS, Krokidi AT,  
481 Navankasattusas S, McKellar SH, Yin M, Kfoury AG, Wever-Pinzon O, Fang JC, Selzman CH,  
482 Chaudhuri D, Rutter J and Drakos SG. The Role of Nonglycolytic Glucose Metabolism in  
483 Myocardial Recovery Upon Mechanical Unloading and Circulatory Support in Chronic Heart  
484 Failure. *Circulation*. 2020;142:259-274.
- 485 5. Diakos NA, Navankasattusas S, Abel ED, Rutter J, McCreath L, Ferrin P, McKellar SH,  
486 Miller DV, Park SY, Richardson RS, Deberardinis R, Cox JE, Kfoury AG, Selzman CH, Stehlik J,  
487 Fang JC, Li DY and Drakos SG. Evidence of Glycolysis Up-Regulation and Pyruvate  
488 Mitochondrial Oxidation Mismatch During Mechanical Unloading of the Failing Human Heart:  
489 Implications for Cardiac Reloading and Conditioning. *JACC Basic Transl Sci*. 2016;1:432-444.
- 490 6. Klier SA and Mangelsdorf DJ. A Dozen Years of Discovery: Insights into the  
491 Physiology and Pharmacology of FGF21. *Cell Metab*. 2019;29:246-253.
- 492 7. Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, Lee H, Catana C, Klibanski  
493 A, Patwari P and Steinhauser ML. FGF21 and the late adaptive response to starvation in  
494 humans. *J Clin Invest*. 2015;125:4601-11.
- 495 8. Lundsgaard AM, Fritzen AM, Sjoberg KA, Myrmel LS, Madsen L, Wojtaszewski JFP,  
496 Richter EA and Kiens B. Circulating FGF21 in humans is potently induced by short term  
497 overfeeding of carbohydrates. *Mol Metab*. 2017;6:22-29.
- 498 9. Desai BN, Singhal G, Watanabe M, Stevanovic D, Lundasen T, Fisher FM, Mather ML,  
499 Vardeh HG, Douris N, Adams AC, Nasser IA, FitzGerald GA, Flier JS, Skarke C and Maratos-  
500 Flier E. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective  
501 role in ethanol associated liver injury. *Mol Metab*. 2017;6:1395-1406.
- 502 10. Hong ES, Lim C, Choi HY, Lee YK, Ku EJ, Moon JH, Park KS, Jang HC and Choi SH.  
503 Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor  
504 levels are decreased in the visceral fat of patients with type 2 diabetes. *BMJ Open Diabetes  
505 Research & Care*. 2019;7:e000776.
- 506 11. Wang Y-S, Ye J, Cao Y-H, Zhang R, Liu Y, Zhang S-W, Dai W and Zhang Q. Increased  
507 serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and  
508 meta-analysis. *Postgraduate Medical Journal*. 2019;95:134-139.
- 509 12. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA and Tripathy D.  
510 Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2  
511 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance. *Diabetes Care*.  
512 2009;32:1542-1546.
- 513 13. Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T, Nielsen S  
514 and Pedersen BK. Fibroblast growth factor-21 is induced in human skeletal muscles by  
515 hyperinsulinemia. *Diabetes*. 2009;58:2797-801.
- 516 14. Kruse R, Vienberg SG, Vind BF, Andersen B and Hojlund K. Effects of insulin and  
517 exercise training on FGF21, its receptors, and target genes in obesity and type 2 diabetes.  
518 *Diabetologia*. 2017;60:2042-2051.

- 519 15. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA,  
520 Sitges M, Giralt M, van Bilsen M and Villarroya F. Fibroblast growth factor 21 protects against  
521 cardiac hypertrophy in mice. *Nat Commun.* 2013;4:2019.
- 522 16. Ruan CC, Kong LR, Chen XH, Ma Y, Pan XX, Zhang ZB and Gao PJ. A2A Receptor  
523 Activation Attenuates Hypertensive Cardiac Remodeling via Promoting Brown Adipose Tissue-  
524 Derived FGF21. *Cell Metab.* 2018;28:476-489 e5.
- 525 17. Joki Y, Ohashi K, Yuasa D, Shibata R, Ito M, Matsuo K, Kambara T, Uemura Y,  
526 Hayakawa S, Hiramatsu-Ito M, Kanemura N, Ogawa H, Daida H, Murohara T and Ouchi N.  
527 FGF21 attenuates pathological myocardial remodeling following myocardial infarction through  
528 the adiponectin-dependent mechanism. *Biochem Biophys Res Commun.* 2015;459:124-30.
- 529 18. Pol CJ, Pollak NM, Jurczak MJ, Zacharia E, Karagiannides I, Kyriazis ID, Ntziachristos  
530 P, Scerbo DA, Brown BR, Aifantis I, Shulman GI, Goldberg IJ and Drosatos K. Cardiac myocyte  
531 KLF5 regulates body weight via alteration of cardiac FGF21. *Biochim Biophys Acta Mol Basis*  
532 *Dis.* 2019;1865:2125-2137.
- 533 19. Rupérez C, Lerin C, Ferrer-Curriu G, Cairo M, Mas-Stachurska A, Sitges M, Villarroya J,  
534 Giralt M, Villarroya F and Planavila A. Autophagic control of cardiac steatosis through FGF21 in  
535 obesity-associated cardiomyopathy. *Int J Cardiol.* 2018;260:163-170.
- 536 20. Brahma MK, Adam RC, Pollak NM, Jaeger D, Zierler KA, Pöcher N, Schreiber R,  
537 Romauch M, Moustafa T, Eder S, Ruelicke T, Preiss-Landl K, Lass A, Zechner R and Haemmerle  
538 G. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid  
539 homeostasis. *J Lipid Res.* 2014;55:2229-41.
- 540 21. Gan F, Huang J, Dai T, Li M and Liu J. Serum level of fibroblast growth factor 21  
541 predicts long-term prognosis in patients with both diabetes mellitus and coronary artery  
542 calcification. *Ann Palliat Med.* 2020;9:368-374.
- 543 22. Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung  
544 WT, Scott RS, Taskinen MR, Keech AC and Rye KA. The relationship of fibroblast growth factor  
545 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in  
546 Diabetes study. *Diabetologia.* 2015;58:464-73.
- 547 23. Chou RH, Huang PH, Hsu CY, Chang CC, Leu HB, Huang CC, Chen JW and Lin SJ.  
548 Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart  
549 Failure Patients with Preserved Ejection Fraction. *Sci Rep.* 2016;6:33953.
- 550 24. Shen Y, Zhang X, Pan X, Xu Y, Xiong Q, Lu Z, Ma X, Bao Y and Jia W. Contribution of  
551 serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death.  
552 *Cardiovasc Diabetol.* 2017;16:106.
- 553 25. Redondo-Angulo I, Mas-Stachurska A, Sitges M, Tinahones FJ, Giralt M, Villarroya F  
554 and Planavila A. Fgf21 is required for cardiac remodeling in pregnancy. *Cardiovasc Res.*  
555 2017;113:1574-1584.
- 556 26. Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M and  
557 Villarroya F. Fibroblast growth factor 21 protects the heart from oxidative stress. *Cardiovasc*  
558 *Res.* 2015;106:19-31.
- 559 27. Ferrer-Curriu G, Guitart-Mampel M, Rupérez C, Zamora M, Crispi F, Villarroya F,  
560 Fernández-Solà J, Garrabou G and Planavila A. The protective effect of fibroblast growth factor-  
561 21 in alcoholic cardiomyopathy: a role in protecting cardiac mitochondrial function. *J Pathol.*  
562 2021;253:198-208.
- 563 28. Ferrer-Curriu G, Redondo-Angulo I, Guitart-Mampel M, Ruperez C, Mas-Stachurska A,  
564 Sitges M, Garrabou G, Villarroya F, Fernández-Solà J and Planavila A. Fibroblast growth factor-  
565 21 protects against fibrosis in hypertensive heart disease. *J Pathol.* 2019;248:30-40.
- 566 29. Barb D, Bril F, Kalavalapalli S and Cusi K. Plasma Fibroblast Growth Factor 21 Is  
567 Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2  
568 Diabetes. *J Clin Endocrinol Metab.* 2019;104:3327-3336.

- 569 30. Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, Sekiguchi C,  
570 Miyazawa Y, Kusano E, Kanda Y, Asano Y, Kuro OM and Nagata D. Association between  
571 circulating fibroblast growth factor 21 and mortality in end-stage renal disease. *PLoS One*.  
572 2017;12:e0178971.
- 573 31. Wu L, Pan Q, Wu G, Qian L, Zhang J, Zhang L, Fang Q, Zang G, Wang Y, Lau G, Li H and  
574 Jia W. Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-  
575 Related Diseases. *Sci Rep*. 2017;7:16482.
- 576 32. Pekkarinen PT, Skrifvars MB, Lievonen V, Jakkula P, Albrecht L, Loisa P, Tiainen M,  
577 Pettilä V, Reinikainen M and Hästbacka J. Serum fibroblast growth factor 21 levels after out of  
578 hospital cardiac arrest are associated with neurological outcome. *Sci Rep*. 2021;11:690.
- 579 33. Ruiz-Margáin A, Pohlmann A, Ryan P, Schierwagen R, Chi-Cervera LA, Jansen C,  
580 Mendez-Guerrero O, Flores-García NC, Lehmann J, Torre A, Macías-Rodríguez RU and  
581 Trebicka J. Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in  
582 critically ill patients with cirrhosis. *Liver Transpl*. 2018;24:595-605.
- 583 34. Thiessen SE, Vanhorebeek I, Derese I, Gunst J and Van den Berghe G. FGF21 Response  
584 to Critical Illness: Effect of Blood Glucose Control and Relation With Cellular Stress and  
585 Survival. *J Clin Endocrinol Metab*. 2015;100:E1319-27.
- 586 35. Zheng W, Matei N, Pang J, Luo X, Song Z, Tang J and Zhang JH. Delayed recanalization  
587 at 3 days after permanent MCAO attenuates neuronal apoptosis through  
588 FGF21/FGFR1/PI3K/Caspase-3 pathway in rats. *Exp Neurol*. 2019;320:113007.
- 589 36. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M,  
590 Rosenblatt KP, Kliewer SA and Kuro OM. Tissue-specific expression of betaKlotho and  
591 fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and  
592 FGF21. *J Biol Chem*. 2007;282:26687-26695.
- 593 37. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS and Maratos-Flier E. Hepatic  
594 fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid  
595 metabolism in ketotic states. *Cell Metab*. 2007;5:426-37.
- 596 38. Refsgaard Holm M, Christensen H, Rasmussen J, Johansen ML, Schou M, Faber J and  
597 Kistorp C. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of  
598 chronic inflammation. *ESC Heart Fail*. 2019;6:983-991.
- 599 39. Ong KL, Campbell S, Wu BJ, McClelland RL, Kokkinos J, Szklo M, Polak JF, Allison MA  
600 and Rye KA. Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and  
601 cardiovascular events: Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*. 2019;287:46-53.
- 602 40. Li Q, Zhang Y, Ding D, Yang Y, Chen Q, Su D, Chen X, Yang W, Qiu J and Ling W.  
603 Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With  
604 Coronary Artery Disease. *J Clin Endocrinol Metab*. 2016;101:4886-4894.
- 605 41. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi  
606 M, Kuro-o M, Mangelsdorf DJ and Kliewer SA. Research resource: Comprehensive expression  
607 atlas of the fibroblast growth factor system in adult mouse. *Mol Endocrinol*. 2010;24:2050-64.
- 608 42. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso  
609 AW, Lam KS and Xu A. Serum FGF21 levels are increased in obesity and are independently  
610 associated with the metabolic syndrome in humans. *Diabetes*. 2008;57:1246-53.
- 611 43. Schlein C, Talukdar S, Heine M, Fischer AW, Krott LM, Nilsson SK, Brenner MB, Heeren  
612 J and Scheja L. FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in  
613 White and Brown Adipose Tissues. *Cell Metab*. 2016;23:441-53.
- 614 44. Kaufman A, Abuqayyas L, Denney WS, Tillman EJ and Rolph T. AKR-001, an Fc-FGF21  
615 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid  
616 Metabolism in Type 2 Diabetes Patients. *Cell Rep Med*. 2020;1:100057.
- 617 45. Sarabhai T, Kahl S, Szendroedi J, Markgraf DF, Zaharia OP, Barosa C, Herder C,  
618 Wickrath F, Bobrov P, Hwang JH, Jones JG and Roden M. Monounsaturated fat rapidly induces  
619 hepatic gluconeogenesis and whole-body insulin resistance. *JCI Insight*. 2020;5.

- 620 46. Jaworska J, Micielska K, Kozłowska M, Wnorowski K, Skrobecki J, Radzimiński L,  
621 Babińska A, Rodziewicz E, Lombardi G and Ziemann E. A 2-Week Specific Volleyball Training  
622 Supported by the Whole Body Cryostimulation Protocol Induced an Increase of Growth Factors  
623 and Counteracted Deterioration of Physical Performance. *Front Physiol.* 2018;9:1711.
- 624 47. Foo JP, Aronis KN, Chamberland JP and Mantzoros CS. Lack of Day/Night variation in  
625 fibroblast growth factor 21 levels in young healthy men. *Int J Obes (Lond).* 2015;39:945-8.
- 626 48. Besse-Patin A, Montastier E, Vinel C, Castan-Laurell I, Louche K, Dray C, Daviaud D,  
627 Mir L, Marques MA, Thalamas C, Valet P, Langin D, Moro C and Viguerie N. Effect of endurance  
628 training on skeletal muscle myokine expression in obese men: identification of apelin as a novel  
629 myokine. *Int J Obes (Lond).* 2014;38:707-13.
- 630 49. Søbørg S, Andersen ES, Dalsgaard NB, Jarlhelt I, Hansen NL, Hoffmann N, Vilsbøll T,  
631 Chenchar A, Jensen M, Grevengoed TJ, Trammell SAJ, Knop FK and Gillum MP. FGF21, a liver  
632 hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol  
633 ingestion and sustained binge drinking at Oktoberfest. *Mol Metab.* 2018;11:96-103.
- 634 50. Toloza FJK, Mantilla-Rivas JO, Pérez-Matos MC, Ricardo-Silgado ML, Morales-Alvarez  
635 MC, Pinzón-Cortés JA, Pérez-Mayorga M, Arévalo-García ML, Tolosa-González G and Mendivil  
636 CO. Plasma Levels of Myonectin But Not Myostatin or Fibroblast-Derived Growth Factor 21 Are  
637 Associated with Insulin Resistance in Adult Humans without Diabetes Mellitus. *Front*  
638 *Endocrinol (Lausanne).* 2018;9:5.
- 639 51. Hua X, Wang YY, Jia P, Xiong Q, Hu Y, Chang Y, Lai S, Xu Y, Zhao Z and Song J. Multi-  
640 level transcriptome sequencing identifies COL1A1 as a candidate marker in human heart failure  
641 progression. *BMC Med.* 2020;18:2.
- 642 52. Schiano C, Costa V, Aprile M, Grimaldi V, Maiello C, Esposito R, Soricelli A, Colantuoni  
643 V, Donatelli F, Ciccodicola A and Napoli C. Heart failure: Pilot transcriptomic analysis of cardiac  
644 tissue by RNA-sequencing. *Cardiol J.* 2017;24:539-553.
- 645 53. Liu Y, Morley M, Brandimarto J, Hannenhalli S, Hu Y, Ashley EA, Tang WH, Moravec  
646 CS, Margulies KB, Cappola TP and Li M. RNA-Seq identifies novel myocardial gene expression  
647 signatures of heart failure. *Genomics.* 2015;105:83-9.
- 648 54. Yang KC, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, Ewald GA, Mann DL  
649 and Nerbonne JM. Deep RNA sequencing reveals dynamic regulation of myocardial noncoding  
650 RNAs in failing human heart and remodeling with mechanical circulatory support. *Circulation.*  
651 2014;129:1009-21.
- 652 55. Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS,  
653 Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS and  
654 Loscalzo J. Individualized interactomes for network-based precision medicine in hypertrophic  
655 cardiomyopathy with implications for other clinical pathophenotypes. *Nat Commun.*  
656 2021;12:873.
- 657 56. Ren Z, Yu P, Li D, Li Z, Liao Y, Wang Y, Zhou B and Wang L. Single-Cell Reconstruction  
658 of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy.  
659 *Circulation.* 2020;141:1704-1719.
- 660 57. Liu X, Ma Y, Yin K, Li W, Chen W, Zhang Y, Zhu C, Li T, Han B, Liu X, Wang S and Zhou  
661 Z. Long non-coding and coding RNA profiling using strand-specific RNA-seq in human  
662 hypertrophic cardiomyopathy. *Sci Data.* 2019;6:90.
- 663